MAUNA KEA TECHNOLOGIES (1MK) AI Stock Analysis

MAUNA KEA TECHNOLOGIES

(Frankfurt:1MK)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue recoveryThe sharp 2025 revenue rebound shows that demand for the company’s Cellvizio platform can recover after a weak period. If this improvement persists, a larger installed base and greater procedure activity could support recurring probe and service revenue over the next several quarters.

Negative Factors

Deep operating lossesThe deeply negative operating margin shows that the core business is not yet covering its operating cost structure, despite the revenue rebound and strong gross margin. Continued losses could require additional restructuring, funding, or slower investment, limiting the durability of growth.

MAUNA KEA TECHNOLOGIES (1MK) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 18.94M
Dividend Yield: ―
Average Volume (3M): 76.65K
Price to Earnings (P/E): 1.5
Beta (1Y): 0.43
Revenue Growth: 3.38%
EPS Growth: ―
Country: Germany
Employees: 56
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

MAUNA KEA TECHNOLOGIES Business Overview & Revenue Model

Company Description

Mauna Kea Technologies SA operates as a medical device enterprise, producing and distributing its offerings throughout Europe and worldwide. Its product line serves various medical specialties such as gastroenterology, pulmonology, and urology. Centr...

MAUNA KEA TECHNOLOGIES Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:1MK against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FR:ALERS	58Neutral	EUR 258.39M	37.57	3.89%	―	6.28%	204.56%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:ALIKO	46Neutral	EUR 22.42M	-5.16	-22.03%	―	37.28%	7.83%
FR:ALTHE	46Neutral	EUR 51.65M	-6.56	453.10%	―	-16.98%	20.31%
FR:ALNOV	45Neutral	EUR 31.94M	-0.75	-159.70%	―	10.36%	29.41%
FR:ALMDT	43Neutral	EUR 180.85M	-2.87	271.64%	―	2.16%	-5.26%

* Healthcare Sector Average

Performance Comparison

DE:1MK and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:1MK	MAUNA KEA TECHNOLOGIES	0.08	0.02	27.27%
FR:ALTHE	Theraclion SA	0.68	-0.06	-8.24%
FR:ALNOV	Novacyt S.A.	0.43	-0.03	-5.43%
FR:ALERS	Eurobio-Scientific SA	26.30	2.15	8.90%
FR:ALIKO	Ikonisys SA	1.41	-0.05	-3.42%
FR:ALMDT	Median Technologies	3.53	0.55	18.66%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

MAUNA KEA TECHNOLOGIES AI Stock Analysis